Laboratory Corporation of America Holdings (LH) - Net Assets
Based on the latest financial reports, Laboratory Corporation of America Holdings (LH) has net assets worth $8.75 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.09 Billion) and total liabilities ($10.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Laboratory Corporation of America Holdin tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.75 Billion |
| % of Total Assets | 45.82% |
| Annual Growth Rate | 9.49% |
| 5-Year Change | -16.1% |
| 10-Year Change | 56.43% |
| Growth Volatility | 38.86 |
Laboratory Corporation of America Holdings - Net Assets Trend (1989–2025)
This chart illustrates how Laboratory Corporation of America Holdings's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Laboratory Corporation of America Holdin to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Laboratory Corporation of America Holdings (1989–2025)
The table below shows the annual net assets of Laboratory Corporation of America Holdings from 1989 to 2025. For live valuation and market cap data, see LH stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.64 Billion | +7.07% |
| 2024-12-31 | $8.07 Billion | +2.23% |
| 2023-12-31 | $7.89 Billion | -22.00% |
| 2022-12-31 | $10.12 Billion | -1.73% |
| 2021-12-31 | $10.29 Billion | +8.85% |
| 2020-12-31 | $9.46 Billion | +25.06% |
| 2019-12-31 | $7.56 Billion | +8.18% |
| 2018-12-31 | $6.99 Billion | +4.03% |
| 2017-12-31 | $6.72 Billion | +21.72% |
| 2016-12-31 | $5.52 Billion | +7.38% |
| 2015-12-31 | $5.14 Billion | +81.15% |
| 2014-12-31 | $2.84 Billion | +14.39% |
| 2013-12-31 | $2.48 Billion | -9.87% |
| 2012-12-31 | $2.75 Billion | +9.08% |
| 2011-12-31 | $2.52 Billion | -4.22% |
| 2010-12-31 | $2.63 Billion | +17.19% |
| 2009-12-31 | $2.25 Billion | +24.25% |
| 2008-12-31 | $1.81 Billion | +4.89% |
| 2007-12-31 | $1.73 Billion | -12.74% |
| 2006-12-31 | $1.98 Billion | +4.85% |
| 2005-12-31 | $1.89 Billion | -4.48% |
| 2004-12-31 | $1.97 Billion | +4.12% |
| 2003-12-31 | $1.90 Billion | +15.39% |
| 2002-12-31 | $1.64 Billion | +51.38% |
| 2001-12-31 | $1.09 Billion | +23.71% |
| 2000-12-31 | $877.40 Million | +19.50% |
| 1999-12-31 | $734.20 Million | +7.78% |
| 1998-12-31 | $681.20 Million | +8.13% |
| 1997-12-31 | $630.00 Million | +144.09% |
| 1996-12-31 | $258.10 Million | -37.29% |
| 1995-12-31 | $411.60 Million | +147.95% |
| 1994-12-31 | $166.00 Million | +17.90% |
| 1993-12-31 | $140.80 Million | -33.74% |
| 1992-12-31 | $212.50 Million | -35.76% |
| 1991-12-31 | $330.80 Million | +28.87% |
| 1990-12-31 | $256.70 Million | -22.21% |
| 1989-12-31 | $330.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Laboratory Corporation of America Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8752.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $8.64 Billion | 100.23% |
| Common Stock | $7.50 Million | 0.09% |
| Other Comprehensive Income | $-27.60 Million | -0.32% |
| Total Equity | $8.62 Billion | 100.00% |
Laboratory Corporation of America Holdings Competitors by Market Cap
The table below lists competitors of Laboratory Corporation of America Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Helvetia Holding AG
SW:HBAN
|
$20.98 Billion |
|
Shenzhen Han's CNC Technology Co. Ltd.
SHE:301200
|
$20.98 Billion |
|
AMADEUS IT GRP ADR EO-001
F:AI3B
|
$21.00 Billion |
|
Norsk Hydro ASA
OL:NHY
|
$21.03 Billion |
|
VOLKSWAGEN AG VZ ADR1/10
F:VOWB
|
$20.97 Billion |
|
Estee Lauder Companies Inc
NYSE:EL
|
$20.97 Billion |
|
International Consolidated Airlines Group S.A
MC:IAG
|
$20.96 Billion |
|
InterGlobe Aviation Limited
NSE:INDIGO
|
$20.96 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laboratory Corporation of America Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,052,200,000 to 8,619,800,000, a change of 567,600,000 (7.0%).
- Net income of 876,500,000 contributed positively to equity growth.
- Dividend payments of 240,700,000 reduced retained earnings.
- Share repurchases of 450,000,000 reduced equity.
- Other comprehensive income increased equity by 234,000,000.
- Other factors increased equity by 147,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $876.50 Million | +10.17% |
| Dividends Paid | $240.70 Million | -2.79% |
| Share Repurchases | $450.00 Million | -5.22% |
| Other Comprehensive Income | $234.00 Million | +2.71% |
| Other Changes | $147.80 Million | +1.71% |
| Total Change | $- | 7.05% |
Book Value vs Market Value Analysis
This analysis compares Laboratory Corporation of America Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 30.87x to 2.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-12-31 | $8.29 | $255.82 | x |
| 1990-12-31 | $6.45 | $255.82 | x |
| 1991-12-31 | $8.36 | $255.82 | x |
| 1992-12-31 | $5.63 | $255.82 | x |
| 1993-12-31 | $3.94 | $255.82 | x |
| 1994-12-31 | $4.82 | $255.82 | x |
| 1995-12-31 | $9.20 | $255.82 | x |
| 1996-12-31 | $5.25 | $255.82 | x |
| 1997-12-31 | $12.81 | $255.82 | x |
| 1998-12-31 | $13.52 | $255.82 | x |
| 1999-12-31 | $13.48 | $255.82 | x |
| 2000-12-31 | $15.63 | $255.82 | x |
| 2001-12-31 | $7.68 | $255.82 | x |
| 2002-12-31 | $11.20 | $255.82 | x |
| 2003-12-31 | $12.46 | $255.82 | x |
| 2004-12-31 | $13.49 | $255.82 | x |
| 2005-12-31 | $13.23 | $255.82 | x |
| 2006-12-31 | $14.84 | $255.82 | x |
| 2007-12-31 | $14.22 | $255.82 | x |
| 2008-12-31 | $14.91 | $255.82 | x |
| 2009-12-31 | $20.61 | $255.82 | x |
| 2010-12-31 | $25.00 | $255.82 | x |
| 2011-12-31 | $24.79 | $255.82 | x |
| 2012-12-31 | $27.90 | $255.82 | x |
| 2013-12-31 | $27.03 | $255.82 | x |
| 2014-12-31 | $32.64 | $255.82 | x |
| 2015-12-31 | $49.16 | $255.82 | x |
| 2016-12-31 | $52.79 | $255.82 | x |
| 2017-12-31 | $65.49 | $255.82 | x |
| 2018-12-31 | $67.95 | $255.82 | x |
| 2019-12-31 | $76.74 | $255.82 | x |
| 2020-12-31 | $96.29 | $255.82 | x |
| 2021-12-31 | $105.37 | $255.82 | x |
| 2022-12-31 | $110.22 | $255.82 | x |
| 2023-12-31 | $89.90 | $255.82 | x |
| 2024-12-31 | $95.41 | $255.82 | x |
| 2025-12-31 | $102.86 | $255.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laboratory Corporation of America Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.17%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.28%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 2.13x
- Recent ROE (10.17%) is below the historical average (15.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | 19.61% | 16.08% | 1.09x | 1.12x | $31.70 Million |
| 1990 | 32.18% | 16.46% | 1.34x | 1.46x | $56.93 Million |
| 1991 | 31.41% | 17.20% | 1.47x | 1.24x | $70.82 Million |
| 1992 | 19.11% | 5.63% | 1.51x | 2.25x | $19.35 Million |
| 1993 | 80.04% | 14.82% | 1.30x | 4.16x | $98.62 Million |
| 1994 | 18.13% | 3.45% | 0.86x | 6.10x | $13.50 Million |
| 1995 | -2.99% | -0.86% | 0.78x | 4.46x | $-53.46 Million |
| 1996 | -59.47% | -9.55% | 0.84x | 7.43x | $-179.31 Million |
| 1997 | -16.97% | -7.04% | 0.92x | 2.63x | $-169.90 Million |
| 1998 | 10.10% | 4.27% | 0.98x | 2.41x | $680.00K |
| 1999 | 8.91% | 3.85% | 1.07x | 2.17x | $-8.02 Million |
| 2000 | 12.78% | 5.84% | 1.15x | 1.90x | $24.36 Million |
| 2001 | 16.54% | 8.16% | 1.14x | 1.78x | $70.96 Million |
| 2002 | 15.80% | 10.15% | 0.96x | 1.62x | $93.43 Million |
| 2003 | 16.93% | 10.92% | 0.86x | 1.80x | $131.41 Million |
| 2004 | 18.16% | 11.77% | 0.86x | 1.80x | $163.07 Million |
| 2005 | 20.48% | 11.61% | 0.86x | 2.06x | $197.63 Million |
| 2006 | 21.83% | 12.02% | 0.90x | 2.02x | $233.89 Million |
| 2007 | 27.64% | 11.72% | 0.93x | 2.53x | $304.27 Million |
| 2008 | 27.51% | 10.31% | 0.96x | 2.77x | $295.67 Million |
| 2009 | 24.16% | 11.57% | 0.97x | 2.16x | $318.45 Million |
| 2010 | 21.18% | 11.16% | 0.81x | 2.35x | $294.70 Million |
| 2011 | 20.59% | 9.38% | 0.90x | 2.45x | $267.33 Million |
| 2012 | 21.46% | 10.28% | 0.83x | 2.51x | $311.36 Million |
| 2013 | 23.13% | 9.88% | 0.84x | 2.80x | $325.68 Million |
| 2014 | 18.12% | 8.50% | 0.82x | 2.59x | $229.15 Million |
| 2015 | 8.84% | 5.03% | 0.61x | 2.89x | $-57.61 Million |
| 2016 | 13.30% | 7.59% | 0.68x | 2.59x | $181.52 Million |
| 2017 | 18.64% | 12.15% | 0.63x | 2.44x | $587.79 Million |
| 2018 | 12.68% | 7.80% | 0.70x | 2.32x | $186.56 Million |
| 2019 | 10.89% | 7.13% | 0.64x | 2.38x | $67.10 Million |
| 2020 | 16.49% | 11.13% | 0.70x | 2.13x | $612.44 Million |
| 2021 | 23.14% | 18.10% | 0.64x | 1.98x | $1.35 Billion |
| 2022 | 12.67% | 10.78% | 0.59x | 2.00x | $269.44 Million |
| 2023 | 5.31% | 3.44% | 0.73x | 2.12x | $-369.50 Million |
| 2024 | 9.26% | 5.73% | 0.71x | 2.28x | $-59.22 Million |
| 2025 | 10.17% | 6.28% | 0.76x | 2.13x | $14.52 Million |
Industry Comparison
This section compares Laboratory Corporation of America Holdings's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $655,728,646
- Average return on equity (ROE) among peers: -117.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laboratory Corporation of America Holdings (LH) | $8.75 Billion | 19.61% | 1.18x | $20.98 Billion |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.88 Million | -205.65% | 3.66x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About Laboratory Corporation of America Holdings
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcoh… Read more